CAMP4 Therapeutics Corporation(CAMP)

Biotechnology · Cambridge, MA

$3.85-0.16 (-3.99%)

Delayed quote: Oct 6, 2026, 12:15 PM EDT

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T16:16:03.780Z.

Stored calculation inputs

Calculation as of: 2026-10-06T16:16:03.780Z.

Quote observation: 2026-10-06T16:15:08.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 241,593,545
Total debt · period ending 2026-06-30: 2,372,000
Cash · period ending 2026-06-30: 87,128,000
TTM operating EBITDA · period ending 2026-06-30: -50,561,000

FMP input reference: 5c882cca81b2c0fe2c09916b57b0a50c93804d18514abf2397940823ad07c5bd

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

CAMP EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

CAMP Competitors' EV/EBITDA Ratio

CAMP

CAMP4 Therapeutics Corporation

Current

Market Cap

$241.59M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GALT

Galectin Therapeutics Inc.

vs CAMP

Market Cap

$242.35M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GLSI

Greenwich LifeSciences, Inc.

vs CAMP

Market Cap

$242.52M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AKBA

Akebia Therapeutics, Inc.

vs CAMP

Market Cap

$239.98M

EV/EBITDA Ratio

N/A

TTM Avg

21.13x

3Y Avg

83.14x

5Y Avg

83.14x

LFCR

Lifecore Biomedical, Inc.

vs CAMP

Market Cap

$243.71M

EV/EBITDA Ratio

N/A

TTM Avg

28.93x

3Y Avg

31.09x

5Y Avg

27.66x

IFRX

InflaRx N.V.

vs CAMP

Market Cap

$239.19M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IVVD

Invivyd, Inc.

vs CAMP

Market Cap

$244.52M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAUT

Nautilus Biotechnolgy, Inc.

vs CAMP

Market Cap

$245.13M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

QSI

Quantum-Si incorporated

vs CAMP

Market Cap

$246.29M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

QTTB

Q32 Bio Inc.

vs CAMP

Market Cap

$246.15M

EV/EBITDA Ratio

6.63x

TTM Avg

4.45x

3Y Avg

4.45x

5Y Avg

4.45x

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
CAMP4 Therapeutics Corporation (CAMP)	$241.59M	N/A	N/A	N/A	N/A
Galectin Therapeutics Inc. (GALT)vs ›	$242.35M	N/A	N/A	N/A	N/A
Greenwich LifeSciences, Inc. (GLSI)vs ›	$242.52M	N/A	N/A	N/A	N/A
Akebia Therapeutics, Inc. (AKBA)vs ›	$239.98M	N/A	21.13x	83.14x	83.14x
Lifecore Biomedical, Inc. (LFCR)vs ›	$243.71M	N/A	28.93x	31.09x	27.66x
InflaRx N.V. (IFRX)vs ›	$239.19M	N/A	N/A	N/A	N/A
Invivyd, Inc. (IVVD)vs ›	$244.52M	N/A	N/A	N/A	N/A
Nautilus Biotechnolgy, Inc. (NAUT)vs ›	$245.13M	N/A	N/A	N/A	N/A
Quantum-Si incorporated (QSI)vs ›	$246.29M	N/A	N/A	N/A	N/A
Q32 Bio Inc. (QTTB)vs ›	$246.15M	6.63x	4.45x	4.45x	4.45x

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics